secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055650
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio reports Q1 net loss $9.1M; CTAs cleared for two clinical trials
----------------------------------------------------------------------------

- Net loss narrowed to $9.1M ($1.66/sh) from $19.0M ($4.46) YoY; cash $113M funds ops into H2 2025.
- CTAs cleared for Phase 1a/1b of ABI-5366 (genital herpes) and Phase 1b of ABI-4334 (HBV); both on track by mid-2024.
- Interim data expected: ABI-5366 Ph1a in Q3 2024; ABI-4334 Ph1b by year-end 2024.
- Two more candidates (ABI-1179 and ABI-6250) expected to enter clinic by end of 2024.
- Revenue from Gilead collaboration $5.8M in Q1 2024 vs $0 prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024055650/0000950170-24-055650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024055650/asmb-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer